Employer-insured enrollees spend more on prescriptions than health-insurance exchange enrollees, but the groups spend the same amount of money when it comes to specialty medications, a study shows.
A study found that cost-effectiveness and clinical-effectiveness measures often point to the same treatment protocol.
Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.
The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.
Three studies take on different angles of the patient experience. Spoiler alert: no cost increases are mentioned.
The effectiveness of new drugs is in decline, says an analysis, and researchers say comparative studies should look beyond efficacy measures.
A study highlights medical service trends among patients with high-deductible plans but lacks insight on health impact and long-term costs.
Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.
Members of the House Energy and Commerce committee alternatively blamed and excused the FDA over the meningitis outbreak that has killed 32 patients.
The drug industry gets a lot of grief over its online communications to consumers, but a study has found that sites posted by doctors and hospitals and touting surgeries are often dreadful—and far less tightly regulated.
About 65% of the 1,800 physicians surveyed in a 2009 study discussed in Health Affairs support disclosing potential conflicts of interest to patients.
- McCann Health forms new global consultancy
- Alexion uses superheroes, social media to raise rare-disease awareness
- Five things for pharma marketers to know: Tuesday, September 20, 2016
- Five things for pharma marketers to know: Wednesday, September 21, 2016
- Five things for pharma marketers to know: Monday, September 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- The FDA approves Amgen's biosimilar version of Humira
- Five things for pharma marketers to know: Friday, September 23, 2016
- Five things for pharma marketers to know: Thursday, September 22, 2016
- Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election
- The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study